Physician profile
Timber Lea Wright
NPI 1497452320
$751.14
in general payments reported to CMS, 2019-2025
15 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $286 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $147.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $135.47 | 2023-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $93.93 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $80.56 | 2024-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $73.29 | 2024-2025 | |
| Novo Nordisk INC | $40.67 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $32.67 | 2023-2024 | Yupelri |
| Astellas Pharma US INC | $25.89 | 2024 | Veozah |
| Abbvie INC. | $21.98 | 2024 | |
| Viatris Specialty LLC | $19.06 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.77 | 2025 | Relistor, Trulance |
| Philips North America LLC | $17.77 | 2024 | (Ak6) Vest Therapy |
| Glaxosmithkline, LLC. | $15.83 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $13.53 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timber Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.